These findings would agree with recent studies showing that serum VIP levels can be used as a prognostic biomarker in early arthritis given that, although no differences in serum neuropeptide levels between patients and healthy donors have been reported, those patients with low baseline levels have a poorer clinical course [34,35]. The gene discussed is VIP; the disease is arthritic joint disease.